The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Cancer treatment cost in the United States: Has the burden shifted over time?
Abstract
BACKGROUND: There has not been a comprehensive analysis of how aggregate cancer costs have changed over time. The authors present 1) updated estimates of the prevalence and total cost of cancer for select payers and how these have changed over the past 2 decades; and 2) for each payer, the distribution of payments by type of service over time to assess whether there have been shifts in cancer treatment settings. METHODS: Pooled data from the 2001 through 2005 Medical Expenditure Panel Survey and the 1987 National Medical Care Expenditure Survey were used for the analysis. The authors used an econometric approach to estimate cancer‐attributable medical expenditures by payer and type of service. RESULTS: In 1987, the total medical cost of cancer (in 2007 US dollars) was $24.7 billion. Private payers financed the largest share of the total (42%), followed by Medicare (33%), out of pocket (17%), other public (7%), and Medicaid (1%). Between 1987 and the 2001 to 2005 period, the total medical cost of cancer increased to $48.1 billion. In 2001 to 2005, the shares of cancer costs were: private insurance (50%), Medicare (34%), out of pocket (8%), other public (5%), and Medicaid (3%). The share of total cancer costs that resulted from inpatient admissions fell from 64.4% in 1987 to 27.5% in 2001 to 2005. CONCLUSIONS: The authors identified 3 trends in the total costs of cancer: 1) the medical costs of cancer have nearly doubled; 2) cancer costs have shifted away from the inpatient setting; and 3) the share of these costs paid for by private insurance and Medicaid have increased. Cancer 2010. Published 2010 by American Cancer Society.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“It was estimated that $74.9 billion of the health care costs in 2013 were for uncompensated care received by those without insurance.30”
From US Health Care Spending by Payer and Health Condition, 1996-2016 (2020) · cites this paper as [30]
Citations
Cites
Effect of Screening and Adjuvant Therapy on Mortality from Breast Cancer
Berry, D. A., Cronin, K. A., Plevritis, S. K., Fryback, D. G., Clarke, L. D., Zelen, M., Mandelblatt, J. S., Yakovlev, A. Y., Habbema, J. D. F., & Feuer, E. J. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050518 · Cited by 2,456
Estimating log models: to transform or not to transform?
Manning, W. G., & Mullahy, J. (2001) · Journal of Health Economics · doi:10.1016/s0167-6296(01)00086-8 · Cited by 1,790
Jemal, A., Thun, M. J., Ries, L. A. G., Howe, H. L., Weir, H. K., Ward, E., Wu, X., Eheman, C. R., Anderson, R. N., Ajani, U. A., et al. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn389 · Cited by 961
Cost of Care for Elderly Cancer Patients in the United States
Yabroff, K. R., Lamont, E. B., Mariotto, A. B., Warren, J. L., Topor, M. A., Meekins, A., & Brown, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn103 · Cited by 700
The Price Tag on Progress — Chemotherapy for Colorectal Cancer
Schrag, D. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048143 · Cited by 437
Evaluation of Trends in the Cost of Initial Cancer Treatment
Warren, J. L., Yabroff, K. R., Meekins, A., Topor, M. A., Lamont, E. B., & Brown, M. L. (2008) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djn175 · Cited by 388
Use of a Self-Report-Generated Charlson Comorbidity Index for Predicting Mortality
Chaudhry, S. I., Jin, L., & Meltzer, D. (2005) · Medical Care · doi:10.1097/01.mlr.0000163658.65008.ec · Cited by 368
The Medical Expenditure Panel Survey: a national health information resource.
(1996) · PubMed · Cited by 338
Patient Time Costs Associated With Cancer Care
Yabroff, K. R., Davis, W. W., Lamont, E. B., Fahey, A., Topor, M. A., Brown, M. L., & Warren, J. L. (2007) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djk001 · Cited by 219
Risk Factors for Melanoma by Body Site
Cho, E., ROSNER, B. A., & Colditz, G. A. (2005) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-04-0632 · Cited by 214
Research works printed but not linked: 1
- DeNavas‐Walt C, 2006, Income, poverty, and health insurance coverage in the United States: 2005. US Census Bureau, Current Population Reports, P60‐231
Cited by
Sorted by citations
Items 101–156 of 156
Dinan, M. A., Curtis, L. H., Carpenter, W. R., Biddle, A. K., Abernethy, A. P., Patz, E. F., Schulman, K. A., & Weinberger, M. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000102 · Cited by 8
The quality of economic studies of cancer pharmacogenomics: a quantitative appraisal of the evidence
Yang, M., Patil, D. S., Tufail, W., & Issa, A. M. (2013) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1586/14737167.2013.838023 · Cited by 8
Tang, D. H., Alberts, D. S., Nevins, R., Sullivan, S., & Skrepnek, G. H. (2012) · Journal of Occupational and Environmental Medicine · doi:10.1097/jom.0b013e31827943e0 · Cited by 8
The burden of gynecological cancer management in Northern Nigeria
Oguntayo, A., Zayyan, M., Akpar, M., Kolawole, A. O., & Adewuyi, S. A. (2013) · Open Journal of Obstetrics and Gynecology · doi:10.4236/ojog.2013.38115 · Cited by 8
Drug Treatment Value in a Changing Oncology Landscape: A Literature and Provider Perspective
Frois, C., Howe, A., Jarvis, J. L., Grice, K. L., Wong, K. S., Zacker, C., & Sasané, R. (2019) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2019.25.2.246 · Cited by 7
Estimating medical expenditures spent on rule‐out diagnoses in Japan
Tanihara, S., Okamoto, E., & Une, H. (2011) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2010.01601.x · Cited by 7
Cost information of chemotherapy for cervical and endometrial cancer in J apan
Kamijo, Y., & Ichikawa, M. (2013) · Japan Journal of Nursing Science · doi:10.1111/jjns.12020 · Cited by 7
Economic burden of gastrointestinal cancer: estimation and importance
Ashtari, S., & Vahedi, M. (2014) · Translational gastrointestinal cancer · Cited by 7
Predicting county‐level cancer incidence rates and counts in the USA
Yu, B. (2013) · Statistics in Medicine · doi:10.1002/sim.5833 · Cited by 7
Zhou, L., Zhang, M., Kong, L.-Q., Lyman, G. H., Wang, K., Lü, W., Feng, Q., Wei, B., & Zhao, L. P. (2017) · Cancer Investigation · doi:10.1080/07357907.2017.1296156 · Cited by 7
Torkki, P. M., Leskelä, R., Bugge, C., Torfadottir, J. E., & Karjalainen, S. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2124883 · Cited by 6
Oncology Payment Reform to Achieve Real Health Care Reform
McClellan, M., & Thoumi, A. I. (2015) · Journal of Oncology Practice · doi:10.1200/jop.2015.004655 · Cited by 6
Hong, N. J. L., Liu, N., Wright, F. C., MacKinnon, M., Seung, S. J., Earle, C. C., Gradin, S., Sati, S., Buchman, S., & Mittmann, N. (2020) · JCO Oncology Practice · doi:10.1200/jop.19.00397 · Cited by 6
Rai, P., Shen, C., Kolodney, J. A., Kelly, K. M., Scott, V., & Sambamoorthi, U. (2020) · Immunotherapy · doi:10.2217/imt-2020-0152 · Cited by 5
Berta, P., Lovaglio, P. G., & Verzillo, S. (2021) · Health Policy · doi:10.1016/j.healthpol.2021.06.005 · Cited by 5
Smith, W. H., Parikh, A. B., Li, L., Sanderson, M. F., Liu, M., Mazumdar, M., Isola, L. M., & Dharmarajan, K. V. (2020) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2020.100218 · Cited by 5
Tariq, M. R., Ali, S. W., Fatima, N., Jabeen, A., Qazi, A. S., Hameed, A., & Safdar, W. (2023) · Cancer treatment and research · doi:10.1007/978-3-031-27156-4_4 · Cited by 5
Seshachalam, A., Rathnam, K., Mahathi, K., Senthil, V., Yathev, S., & Niraimathi, K. (2022) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_150_22 · Cited by 5
Lindhardt, C. L., Mattsson, T. O., & Mebrouk, J. J. (2020) · Applied Nursing Research · doi:10.1016/j.apnr.2020.151268 · Cited by 4
Liu, Y., Wang, S., Li, L., Xu, Y., Shen, Y., & Shih, Y. T. (2023) · Value in Health · doi:10.1016/j.jval.2023.06.003 · Cited by 4
Daroudi, R., Mirzania, M., & Zendehdel, K. (2015) · International Journal of Health Policy and Management · doi:10.15171/ijhpm.2015.186 · Cited by 4
Concerns of stem cell transplant patients during routine ambulatory assessment
Sheldon, L. K., Kazmi, M., Klein, C., & Berry, D. L. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s38567 · Cited by 4
The Medicaid Rebate: Changes in Oncology Drug Prices After the Affordable Care Act
Tehrani, A. B., & Carroll, N. V. (2017) · Applied Health Economics and Health Policy · doi:10.1007/s40258-017-0314-1 · Cited by 4
Parikh, A. B., Smith, W. H., Sanderson, M. F., Dharmarajan, K. V., Liu, M., Isola, L. M., & Ennis, R. D. (2019) · Journal of Oncology Practice · doi:10.1200/jop.18.00560 · Cited by 4
Zhang, C., Ding, Y., & Peng, Q. (2021) · Health Information Science and Systems · doi:10.1007/s13755-021-00153-9 · Cited by 4
Subramanian, S., Tangka, F. K. L., Hoover, S., Nadel, M. R., Smith, R. W., Atkin, W. S., & Patnick, J. (2016) · Journal of Public Health Management and Practice · doi:10.1097/phh.0000000000000386 · Cited by 4
Self-citationBecerra, A. Z., Probst, C. P., Fleming, F. J., Xu, Z., Aquina, C. T., Justiniano, C. F., Boodry, C. I., Swanger, A. A., Noyes, K., Katz, A. W., et al. (2017) · American Journal of Hospice and Palliative Medicine® · doi:10.1177/1049909117706959 · Cited by 4
Economic Evaluations of Hematological Malignancies Compared with Solid Tumors
Batty, N. (2014) · Journal of Leukemia · doi:10.4172/2329-6917.1000129 · Cited by 3
Deficiencies of methods applied in cost effectiveness analysis of hematological malignancies
Batty, N., Shatzel, J. J., Wiles, S. P., Kabalan, M., Sharma, R. S., Pang, J., Yi, D. K., Alatovic, I., Saif, S., Narasimha, D., et al. (2014) · Journal of Cancer Policy · doi:10.1016/j.jcpo.2014.01.002 · Cited by 3
Rao, M., Concannon, T. W., Iovin, R. C., Yu, W. W., Chan, J., Lypas, G., Terasawa, T., Gaylor, J. M., Kong, L., Rausch, A. C., et al. (2013) · Journal of Comparative Effectiveness Research · doi:10.2217/cer.13.61 · Cited by 3
Expanding the Scope of Evidence-Based Cancer Care
Rendell, V. R., Schmocker, R. K., & Abbott, D. E. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2018.05.012 · Cited by 3
Counterpoint: Sowing the Seeds of Standardized Care to Reap Better Patient Outcomes
Jacobson, J. O. (2012) · Journal of Oncology Practice · doi:10.1200/jop.2012.000607 · Cited by 3
The role of social supports on the financial toxicity of Cancer.
Smith, L. C. (2019) · doi:10.18297/etd/3186 · Cited by 3
Improving Quality and Addressing the Rising Costs of Cancer Care: Two Birds, One Stone
Luke, J. J., Mirkin, J. N., & Bach, P. B. (2011) · Journal of Oncology Practice · doi:10.1200/jop.2011.000419 · Cited by 2
Epidemiology of Aging (Socioeconomic Impact)
Brown, C., & Losina, E. (2025) · Medical radiology · doi:10.1007/174_2024_558 · Cited by 2
Kosteneffektivität diagnostischer Verfahren
Langer, A. (2010) · Der Onkologe · doi:10.1007/s00761-010-1906-7 · Cited by 2
Darrudi, A., Poupak, A. H., Daroudi, R., Sargazi, N., Zendehdel, K., Sallnow, L., Motlagh, A. G., Tahmasebi, M., & Nahvijou, A. (2024) · Palliative Care and Social Practice · doi:10.1177/26323524241299819 · Cited by 1
Mortality and costs from acute care surgical emergencies
Sánchez, O., & Ignacio, Á. (2015) · D-Scholarship@Pitt (University of Pittsburgh) · Cited by 1
Current challenges facing pediatric radiation oncology viewed through an economics lens
Halperin, E. C. (2020) · Pediatric Blood & Cancer · doi:10.1002/pbc.28686 · Cited by 1
Recent Health Care Expenditure Trends Among Adult Cancer Survivors in United States, 2009-2016
Rubens, M., Ramamoorthy, V., Saxena, A., Das, S., Bhatt, C. B., Veledar, E., McGranaghan, P., Sundil, S., Shehadeh, N., Viamonte-Ros, A., et al. (2020) · American Journal of Clinical Oncology · doi:10.1097/coc.0000000000000670 · Cited by 1
CAN LIFESTYLE MODIFICATION LOWER THE RISK OF PROSTATE CANCER?
Mgbakor, A. C., & Ogbonna, A. O. (2010) · British Journal of Urology · doi:10.1111/j.1464-410x.2010.09915_2.x · Cited by 1
Geographic Disparities in Cancer Mortality to Incidence Ratios
Buck, K. D. (2014) · Scholar Commons (University of South Carolina)
Krankheitskosten in der Onkologie im internationalen Vergleich
Gundermann, C., Rosée, P. G. L., & Hartmann, M. (2010) · Der Onkologe · doi:10.1007/s00761-010-1903-x
Cancer Treatment for Dual Eligibles: What Are the Costs and Who Pays?
Haber, S. G., Tangka, F. K. L., Richardson, L. C., Sabatino, S. A., & Howard, D. H. (2013) · PubMed
Self-citationLewis, C. M., Chronowski, G. M., Dong, W., Gunn, G. B., Rosenthal, D. I., & Weber, R. S. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-4298-x
Alqahtani, M. E. (2014) · RMIT Research Repository (RMIT University Library) · doi:10.25439/rmt.27576573
Cancer Treatment: the Cost Factor
Smith, S. A. (2014) · West Indian Medical Journal · doi:10.7727/wimj.2014.080
Basic and Clinical Cancer Research in the Healthcare Reform Era
Efird, J. T. (2013) · Journal of Cancer Science & Therapy · doi:10.4172/1948-5956.1000e119
Federal Policies and Prescription Drugs
Tehrani, A. B. (2016) · VCU Scholars Compass (Virginia Commonwealth University) · doi:10.25772/aqd4-1187
A Perspective on the Cost of Cancer Care
Farroni, J. S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-803831-4.00014-2
Epidemiology of Ageing (Socioeconomic Impact)
Rome, B. N., & Losina, E. (2013) · Springer eBooks · doi:10.1007/978-3-642-35579-0_1
Silverman, C., Ng, B. P., Baek, C., & Park, C. (2022) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2022.2064846
Costs of Cancer Care in the Last Five Days of Life in a Low-Resource SettingPreprint
Darrudi, A., Poopak, A. H., Daroudi, R., Sargazi, N., Zendehdel, K., Motlagh, A. G., Tahmasebi, M., & Nahvijou, A. (2023) · Research Square · doi:10.21203/rs.3.rs-2965955/v1
Wealth, health expenditure and cancer: an econometric analysis for European countries
AYDIN, B., & Aydın, E. İ. (2025) · Health Economics Review · doi:10.1186/s13561-025-00665-0
Metadata
- Authors
- Tangka, F. K., Trogdon, J. G., Richardson, L. C., Howard, D., Sabatino, S. A., & Finkelstein, E. A.
- Affiliations
- Centers for Disease Control and Prevention (US)
- RTI International (US)
- Emory University (US)
- National University of Singapore (SG)
- Corresponding author
- Tangka, Florence K.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2010-05-10
- Volume
- 116
- Issue
- 14
- Pages
- 3477-3484
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1590770963
- Cited by
- 156
- References
- 22
- Citations by year
- 2025: 2 · 2024: 3 · 2023: 5 · 2022: 7 · 2021: 11 · 2020: 15 · 2019: 10 · 2018: 9 · 2017: 8 · 2016: 12 · 2015: 11 · 2014: 11 · 2013: 16 · 2012: 14
- FWCI
- 39.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Cancer (publishedVersion, public-domain)
- PubMed (publishedVersion)
- National University of Singapore (submittedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Keywords
- cancer treatment costs, health care costs, cost trends, Medicare, Medicaid, private insurance, out-of-pocket costs, hospitalization, outpatient care, cancer prevalence, United States
- MeSH terms
- Financing, Government, Financing, Personal, Medicare, Humans, Inpatients, Insurance, Health, Medicaid, Neoplasms, Outpatients, United States, Prevalence, Drug Costs, Health Care Costs
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review